Sanofi Japan Looks Past Plavix Hit To New Launches
This article was originally published in PharmAsia News
Sanofi is facing a self-described “transitional period” in Japan and a couple of years of sales contraction as major products are opened up to generics. But the plan is to conduct more than 20 launches, including several biologics and line extensions, in the next four years, its new country president says.
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.